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Abstract
Mutations in the human gene coding for XPD lead to segmental progeria - the premature appearance of some of
the phenotypes normally associated with aging - which may or may not be accompanied by increased cancer
incidence. XPD is required for at least three different critical cellular functions: in addition to participating in the
process of nucleotide excision repair (NER), which removes bulky DNA lesions, XPD also regulates transcription as
part of the general transcription factor IIH (TFIIH) and controls cell cycle progression through its interaction with
CAK, a pivotal activator of cyclin dependent kinases (CDKs). The study of inherited XPD disorders offers the oppor-
tunity to gain insights into the coordination of important cellular events and may shed light on the mechanisms
that regulate the delicate equilibrium between cell proliferation and functional senescence, which is notably
altered during physiological aging and in cancer.
The phenotypic manifestations in the different XPD disorders are the sum of disturbances in the vital processes
carried out by TFIIH and CAK. In addition, further TFIIH- and CAK-independent cellular activities of XPD may also
play a role. This, added to the complex feedback networks that are in place to guarantee the coordination
between cell cycle, DNA repair and transcription, complicates the interpretation of clinical observations. While
results obtained from patient cell isolates as well as from murine models have been elementary in revealing such
complexity, the Drosophila embryo has proven useful to analyze the role of XPD as a cell cycle regulator indepen-
dently from its other cellular functions. Together with data from the biochemical and structural analysis of XPD and
of the TFIIH complex these results combine into a new picture of the XPD activities that provides ground for a
better understanding of the patophysiology of XPD diseases and for future development of diagnostic and
therapeutic tools.
Review
Evolution often strives for simplification; it may be
advantageous for organisms to preserve resources by
using few molecules to fulfill many different tasks, in
particular when these functions are spatially or tempo-
rally separated. But on the flip side of the same coin,
reducing redundancy implies the hazard of multiple
consequences upon malfunctioning of a single key ele-
ment. The multitude of disease phenotypes associated
with defects in the multitask protein XPD perfectly illus-
trates this concept. XPD is a DNA helicase involved in
at least three crucial cellular mechanisms: repair of
DNA damage by nucleotide excision repair (NER), tran-
scription and cell cycle regulation.
XPD disorders
Mutations in the human gene ERCC2/XPD can give rise
to six distinct genetic disorders with a broad variety of
phenotypes collectively called NER syndromes [1-3].
Aside from XPD mutations, mutations in genes encoding
other components of the NER pathway can also cause
these phenotypes. Therefore we will refer here to XPD
disorders to describe the phenotypical manifestations of
mutations in the gene coding for XPD (Figure 1). One of
the most striking phenotypes shared by these syndromes
is the premature appearance of some, but not all, aging-
related features (termed segmental progeria) such as
marked cancer predisposition, photoaging of skin and
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eyes and progressive tissue deterioration due to either
replicative senescence of stem cells or apoptosis of term-
inally differentiated cells [4-6].
Patients suffering from xeroderma pigmentosum (XP)
are sensitive to sunlight, even a limited UV exposure
leads to the premature onset of skin abnormalities
resembling those associated with normal aging. Skin
abnormalities in XP patients range from pigmentation
defects (dyspigmentation, freckling) to the development
of multiple benign (seborrheic keratoses, actinic kera-
toses) and neoplastic (squamous cell carcinoma, basal
cell carcinoma and melanoma) cutaneous lesions [7].
Occasionally, XP patients develop also progressive ocu-
lar disease and eye cancer. Moreover they are generally
more prone to some internal tumors, particularly of the
lungs and the gastro-intestinal tract. The median age of
onset of malignant neoplastic disease is around 8 years
of age for skin neoplasm, and with this well below that
expected for the general population (50 years for US),
while the frequency of its occurrence is one- to several-
thousand times greater than in the general population
[8]. Most of the mutations causing XP affect genes
encoding components of the NER pathway (Figure 2).
Additional XP mutations are found in XPV, which
encodes a DNA polymerase involved in translesion
DNA synthesis [9]. Primary skin fibroblasts isolated
from XP patients show a drastic reduction in the capa-
city to perform DNA-repair and are hypersensitive to
the killing effects of UV-irradiation [10]. Around 20% of
patients show a severe XP phenotype with neurological
abnormalities emerging at the age of 10-20 years.
Neurological symptoms are mainly due to progressive
neurodegeneration and add to the characteristic UV-
sensitive XP phenotype [11]. Some, but not all, of the
cases presenting neurological defects meet the definition
of the De Sanctis-Cacchione syndrome (DSC), the maxi-
mal form of neurological involvement [8]. These cases
have been grouped as a distinct syndrome named XP
with neurological disease (XP+ND) [2].
Mutations in the CSA and CSB genes specifically
impair the mechanism of transcription-coupled repair
(TC-NER) - one of two branches of the NER pathway
(Figure 2) - giving rise to Cockayne Syndrome (CS) [12].
Similar to XP patients, CS patients show an elevated
sensitivity to sun light, but pigmentation abnormalities
and skin malignancies are absent. Patients have a
Figure 1 The genetic causes of the different NER syndromes are depicted on this table. XP, xeroderma pigmentosum; XP+ND, xeroderma
pigmentosum with neurological disease; TTD, trichothiodystrophy; XP-TTD, complex syndrome with phenotypic manifestations of both XP and
TTD; COFS, cerebro oculo facial skeletal syndrome; CS, Cockayne syndrome; XP-CS, complex syndrome with phenotypic manifestations of both
XP and CS. a Includes the cases described as DeSanctis Cacchione (DSC) syndrome. b Only in rare cases. Mutations in genes encoding
components of the GG-NER pathway (light green) cause the XP syndrome or the one of the three complex syndromes XP+ND, XP-TTD and
XP-CS, all of which are characterized by increased cancer incidence. Mutations in genes specifically involved in the TC-NER branch (dark green)
are associated with CS or the more severe COFS syndrome. Mutations affecting the XPD, XPB or TTDA subunits of the TFIIH complex (blue),
which intervenes in a common step of NER, affect both pathways in addition to transcription and lead to TTD. Reflecting the central role of
TFIIH in the common steps of NER, in transcription and in regulation of the cell cycle, mutations in its components (and in particular of XPD) are
found in most of the syndromes.
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reduced stature, malformed bones and retina, and men-
tal retardation mainly due to degeneration of the white
matter [1,13]. Common segmental progeroid features in
CS are: the loss of subcutaneous fat tissue (cachexia),
sensorineural deafness, retinal degeneration, white mat-
ter hypomyelination and CNS calcification [3]. Mutation
in three of the XP genes, XPB, XPD and XPG can give
rise to combined phenotypes of XP and CS (XP-CS)
with neurological dysfunctions reminiscent of CS
combined with the typical skin abnormalities of XP,
including increased cancer incidence [14,15]. Strikingly,
primary fibroblasts from XP-CS patients are consider-
ably more sensitive to killing by UV irradiation than
cells from XP patients.
Mutations in XPD may also cause trichothiodystrophy
(TTD), this definition encompasses several diseases,
which share the hallmark of sulfur-deficient brittle hair
exhibiting a typical tiger tail pattern under polarized
light [16,17]. Many TTD patients also display enhanced
sun-sensitivity, but as in CS the typical pigmentation
defects and the cancer predisposition observed in XP
are absent [1]. Interestingly, even though skin fibroblasts
from TTD patients show enhanced UV-sensitivity, NER
activity in these cells ranges from acutely defective to
nearly normal with only about half of the cases display-
ing marked NER defects. This apparent absence of cor-
relation between NER activity and severity of the disease
suggests that the phenotypes are not exclusively deter-
mined by the impact of the XPD mutation on NER
[18,19]. Additional TTD traits include progressive cogni-
tive impairment, abnormal face shape and reduced body
size [1,14,20]. Progeroid features in TTD patients are
similar to those observed in CS and XP-CS patients,
including demyelinating neuropathy and brain calcifica-
tions. In addition to the XPD and XPB genes, TTDA -
encoding a structural component of the TFIIH complex
- has also been associated with TTD. Patients displaying
combined features of XP - such as dry skin, skin cancer,
mental and physical impairment - and of TTD - such as
ichthyosis and the typical sulfur-deficient and tiger-tail
patterned hair - are assigned to the combined XP-TTD
syndrome group [21]. This complex clinical manifesta-
tion has so far been associated exclusively with muta-
tions in XPD.
Finally, the allelic XPD combination R681N and R616W
gives rise to the Cerebro-oculo-facial-skeletal syndrome
(COFS). Patients show microcephaly, dysmyelination,
defects in neuronal migration and innervation, affecting
both the grey and the white matter. Additionally, patients
show severe mental retardation, drastically reduced life-
span and often prenatal growth failure [3,14,22]. The fea-
tures of the disease are very similar to CS although
patients show more severe eye and brain defects and fibro-
blast lines isolated from these patients are more sensitive
to the killing effect of UV irradiation than cells isolated
from CS patients [22]. The COFS syndrome was first
described with mutated XPG and CSB genes and was pro-
posed to be a severe allelic form of CS [23].
Figure 2 Nucleotide excision repair (NER) repairs UV-induced
pyrimidine dimers, intra-strand and protein-DNA crosslinks,
and a wide range of bulky chemical adducts [11]. Its two
subpathways global genomic repair (GG-NER) and transcription-
coupled repair (TC-NER) differ in their damage recognition. DNA
distortions anywhere in the genome are recognized by XPC. Lesions
that cause only minor distortions, such as UV-induced cyclobutane
pyrimidine dimers (CPD) are recognized by the damage DNA
binding complex (DDB) composed of DDB1 and DDB2 (encoded by
the XPE gene). DDB induces a strong kink in the DNA, enhancing its
recognition by XPC. The XPC and DDB complexes are dispensable
for the TC-NER subpathway that relies on RNA Pol II for the
recognition of DNA damage. When RNA Pol II encounters a lesion
that blocks its progression, it recruits CSA, CSB and XAB2. Either XPC
in GG-NER or CSB and CSA in TC-NER then recruit further NER
factors, including the transcription factor TFIIH to the damage site.
The XPD and XPB subunits of TFIIH (depicted separately to point
out their essential role in NER) unwind the DNA around the lesion.
This process requires the helicase activity of XPD and the ATPase
(but not the helicase) activity of XPB. XPG stabilizes the interaction
between TFIIH and XPD. The opened denaturation bubble is
stabilized by the XPA complex (XPA and the heterotrimer RNA),
which also participates in the proofreading step (verification of the
presence of a lesion and identification of the damaged strand). The
damaged strand is incised on the 3’ side of the lesion by XPG and
on the 5’ by the ERCC1-XPF heterodimer. The gap left by the
excised oligonucleotide is filled by one of the replicative DNA
polymerases (Pol δ or Pol ε) using the undamaged strand as a
template and sealed by either ligase I or III.
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XPD phenotypes: insights from structural data
Due to the implication of XPD in fundamental processes
such as transcription, NER and cell cycle regulation,
malfunctioning of this enzyme results in pleiotropic
phenotypes. Understanding how different mutations in
the same gene, often changing adjacent aminoacids, dif-
ferentially affect the functionality of XPD requires pro-
found knowledge of the molecular structure of XPD and
of the complexes in which it is integrated.
Structure of the XPD-containing complexes
XPD bridges the core subcomplex of the general tran-
scription factor IIH (core TFIIH) to the CDK activating
kinase (CAK) complex, which also exists as a free tri-
meric complex with a distinct function [24,25]. An addi-
tional quaternary CAK-XPD complex with unknown
biological relevance has been isolated from mammalian
cells [26] as well as from Drosophila embryonic extracts
[27]. Recently, a novel XPD complex has been described
that is distinct from the TFIIH complex; in this MMXD
(MMS19-MIP18-XPD) complex, XPD is found asso-
ciated with MMS19, MIP18 (formerly FMA96B), Ciao1
and ANT2 but no additional TFIIH component [28].
The TFIIH complex is currently the best characterized
XPD complex. It is made up of 10 subunits and defects
in three of them are known to cause NER syndromes;
namely the 5’-3’ helicase XPD, the 3’-5’ helicase XPB and
TTDA/p8, a 8kDa protein required for stabilization of
the complex [29]. In addition to its helicase activity,
TFIIH possesses also kinase activity, which is provided by
the cyclin-dependent kinase 7 (CDK7) and is required for
the transactivation of various transcription factors as well
as for the regulation of RNA Polymerase II (RNA Pol II)
[30-35]. Importantly, the substrate specificity of CDK7 is
dependent on the molecular context; when CDK7 is inte-
grated in the TFIIH complex, it phosphorylates the
C-terminal domain of RNA Pol II in addition to various
transcription factors, while as part of the free CAK com-
plex it shows higher activity towards CDKs such as
CDK1, CDK2, CDK4 and CDK6 [25,36].
Although additional protein-protein interactions with
XPB, p62 and p44 have been proposed to mediate CAK
binding to core TFIIH [25], reduced binding of the XPD
component most drastically affects the composition and
stability of the complex. Analysis of CAK localization
and activity in Drosophila suggested a model in which
XPD, besides anchoring CAK to TFIIH, also acts as a
molecular dispatcher allocating the activity of the CAK/
CDK7 kinase to the appropriate cellular substrates
[37,38]. Additionally, despite not being a TFIIH subunit
per se, the NER protein XPG was also found to associate
with the TFIIH complex by interacting directly with
XPD stabilizing the interaction between TFIIH and the
CAK-XPD complex [39,40]. Remarkably, as observed for
XPD, mutations in XPG also lead to XP or XP-CS
phenotypes, suggesting that part of these phenotypes are
related to a reduced capacity to anchor CAK to TFIIH
resulting in increased free CAK activity.
The function of XPD appears to be modulated by
interaction with the TFIIH complex as full helicase
activity requires the interaction with the TFIIH subunit
p44 and possibly also other subunits [35]. The func-
tional relevance of the XPD-p44 interaction is under-
lined by the high proportion of disease-causing
mutations found in the C-terminal region of XPD
which is required for this interaction [41] (Figure 3A).
Mutations in XPD preventing interaction with p44 as
well as mutations in XPD or other TFIIH subunits (e.g.
TTDA/p8) that affect the stability of the core TFIIH
complex have been suggested to lead to TTD [42].
Interestingly, in a Drosophila TTD model carrying
TFIIH-destabilizing mutations in the genes coding for
the XPB or the p52 subunit, overexpression of TTDA/
p8 suppresses accumulated developmental defects
associated with these mutations [43].
The structure of human TFIIH complex has been
resolved by electron microscopy, revealing that the core
TFIIH subunits fold into a ring structure with a bulge
formed by the CAK component. XPD locates at the
base of this bulge and appears to be integrated into the
ring structure opposite to XPB relative to the bulge and
both XPD and XPB are bound to p44 [44]. While CAK
is required for the function of TFIIH and may have a
role in stabilizing the complex, it is clearly dispensable
for formation of the core TFIIH as this can be formed
in vitro in the absence of the CAK components [44].
From this observation it was proposed that XPD may be
added on top of a preexisting ring, a hypothesis that is
compatible with the hypothesis of a dynamically regu-
lated interaction between the CAK-XPD and the core
complex [37].
3D-structure of XPD
While the helicase activity of XPD is essential during
NER, the role of XPD in transcriptional regulation
depends, rather than on its enzymatic activity, on its
ability to bridge the CAK to the TFIIH core complex.
Similarly, a scaffolding role has also been proposed for
XPD in the regulation of the cell cycle, where XPD is
thought to dynamically regulate the association of CAK
with TFIIH [37]. The crystal structures of the XPD cata-
lytic core from Sulfolobus acidocaldarius and Thermo-
plasma acidophilum have recently been resolved [42,45].
Mapping the different disease-related point mutations in
ERCC2/XPD on these 3D structures provided better
understanding about how such mutations could impact
the catalytic activity of XPD, its framework structure, as
well as its ability to undergo correct protein-protein
interactions with TFIIH and CAK components
(Figure 3).
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XPD is a member of the superfamily 2 (SF2) DNA
helicases, but unlike most SF2 members it unwinds
DNA duplexes with 5’-3’ polarity. The catalytic core of
XPD is comprised of two helicase domains, HD1 and
HD2, which contain 4 and 3, respectively, of the 7 con-
served helicase motifs (Figure 3A). Two additional
accessory domains are inserted into HD1: a 4Fe-S clus-
ter and an Arch domain [46]. The 4FeS cluster domain,
conserved among related SF2 helicases, is inserted in
the N-terminal helicase domain (HD1) between motifs
Ia and II that are equivalent to the Walker A and B
motifs of many ATPases. Besides contributing to the
overall stability of the enzyme, this cluster provides resi-
dues involved in the intramolecular interactions that
form the DNA binding interface and thus is thought to
be critical for helicase activity [42]. In addition, it forms
a pocket that is ideally positioned to accommodate the
damaged DNA strand during the step of damage proof-
reading in NER [45]. Intimate connection to the ATP
binding site (Figure 3B) suggests that the conformation
of the 4Fe-S cluster may be regulated by ATP hydroly-
sis. Moreover, the redox-sensitive binding of the four
cysteine residues of the cluster with four Fe ions may
provide an additional mode of regulation of the
Figure 3 (Adapted from [42]) (A) Linear aminoacid sequence of XPD, the positions of some of the (putative) causative mutations
found in XPD syndromes are indicated [1,10,13,42,45,117]. Alterations considered to be completely inactivating [10] are not shown on this
figure. With two exceptions (an aminoacid insertion at position 582 leading to XP-TTD and a non-sense mutation at position 726 leading to XP)
all the mutations mapped in this drawing cause aminoacid substitutions. The phenotypic manifestation of these mutations is indicated by the
color of the arrow as described in the legend. a COFS is caused by the allelic combination R616W (also found in TTD patients) and D681N (B)
Cartoon representing the 3D structure of XPD according to the solved crystal structures of two bacterial homologues [42,45], the C terminus
(pink) is absent in the bacterial proteins and therefore its location on the cartoon is not based on crystallography data [42]. Arrowheads
represent schematically the predominant localization of mutations in XPD giving rise to the different disorders. XP mutations are found mainly in
the vicinity of the helicase motifs on residues that form the channels binding either ATP or ssDNA. XP-CS mutations are at the interface
between the two helicase domains and affect functional flexibility of the enzyme. In contrast TTD mutations appear to increase the flexibility of
the XPD molecule affecting its framework stability and thereby also important intermolecular interactions such as those required to form the
TFIIH complex. Additional TTD mutations are located in the C terminal part of the molecule outside of the catalytic core, Most of these
mutations abolish interaction with the TFIIH subunit p44 [35].
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enzyme’s conformational states, which are likely to be
critical for interaction with other partners. The Arch
domain forms an arch-shaped structure that joins the
HD2 motor helicase domain to the ATP-helicase
domain and forms a small interface with the 4FeS clus-
ter to make an enclosed tunnel, positioning of the
unwound DNA within this tunnel is likely to be relevant
for the presentation of the damaged site to the NER
machinery components [42].
With the exception of 6 mutations - five of which
cause TTD - positioned in the C-terminal extension of
the HD2 domain, most of the disease causing point
mutations in ERCC2/XPD map within its catalytic core
(Figure 3A). According to their predicted impacts on
DNA or ATP binding, XP mutations tend to alter resi-
dues that form the DNA- and ATP-binding channels,
XP-CS mutations are located at the HD1-HD2 interface
and decrease the functional flexibility of the enzyme,
which is essential during DNA repair. Mutations causing
TTD are generally impacting the framework stability of
the enzyme, which in turn is likely to disturb the inter-
actions with the other components of the TFIIH
complex.
Insights from the molecular functions of XPD and its
complexes
Nucleotide excision repair
Several extrinsic factors like radiation, sunlight and che-
micals but also various intrinsic factors such as free
radicals of metabolic origin, mechanical stress and DNA
replication can alter important biomolecules including,
and perhaps most importantly, nucleic acids. Failure to
repair damage to DNA can lead to cell death or cancer.
Thus, several distinct repair pathways are in place to
preserve the genetic information: homologous recombi-
nation, mismatch repair, DNA strand crosslink repair,
nonhomologous end-joining, base excision repair (BER)
and nucleotide excision repair (NER) [47]. The latter
requires the enzymatic activity of XPD and will thus be
the focus of the following paragraph. NER is elicited by
chemically- and UV-induced helix-distorting lesions,
including cyclobutane pyrimidine dimers (CPD) and 6-4
photoproducts (6-4PP) [48]. In addition, NER can also
recognize and repair small oxidative adducts.
NER is a sophisticated DNA repair mechanism entail-
ing damage recognition and proofreading, incision on
both sides of the lesion followed by removal of a 20-30
nucleotide long DNA fragment, DNA re-synthesis and
ligation. Approximately 30 proteins are involved in one
or both of two NER subpathways: namely the global
genome repair (GG-NER ) and the faster transcription-
coupled repair (TC-NER), which differ in the initial,
damage-recognition steps (Figure 2). In GG-NER, repair
of helix-distorting base damage in the entire genome, is
initiated with damage recognition by the XPC-HR23B
complex. For mildly distorting lesions the access of XPC
is facilitated by XPE. The TFIIH complex is subse-
quently recruited through interaction with XPC. In con-
trast, TC-NER is confined to actively transcribed DNA
regions and is elicited by stalling of the transcribing
RNA Pol II at the site of damage. The stalled polymer-
ase is recognized by the CSB gene product, this allows
the subsequent access of CSA. Then TFIIH is recruited
by CSA and CSB along with XPG to remodel the RNA
Pol II complex. After damage recognition, both path-
ways recruit sequentially the other components of the
repair machinery. The TFIIH helicases XPB and XPD
mediate DNA unwinding then XPA-RPA contributes to
the stabilization of the opened helix by binding to the
single-stranded DNA together with XPG. In addition
XPA and the TFIIH subunits XPB and XPD are
involved in recognition of the damaged strand and
proofreading of damage [49]. Correct positioning of the
two endonucleases XPG and XPF-ERCC1, which cata-
lyze the incision of the DNA 3’ and 5’ of the damage,
requires XPA-RPA. The DNA polymerases δ and ε fill
up the resulting gap using the undamaged strand as
template and ultimately a ligase (either I or III) is
recruited to seal the nick [7,50].
While the role of the core TFIIH complex and of XPD
in NER is well established, it is not clear to what extent
the CAK subcomplex is required for this function; even
though the CAK subcomplex is recruited to the
damaged site, the kinase activity of CDK7 appears to be
dispensable for repair [40]. Moreover, following repair
initiation XPA catalyzes the release of CAK from the
TFIIH complex to favor the binding of additional NER
proteins thereby accelerating NER [51]. Strikingly CAK
has also been shown to negatively regulate XPD
unwinding activity in vitro, suggesting that its release is
a prerequisite for efficient repair [7,50,52].
Transcription and RNA Pol II pausing
XPD and the CAK subcomplex are both required for
full transcriptional activation in vitro, yet genetic and
biochemical data indicate that neither the helicase activ-
ity of XPD nor the kinase activity of CDK7 are essential
for this function. Mutations corrupting the helicase
activity of XPD did not impair the ability of TFIIH to
promote transcription in vitro [41,53]; similarly, a TFIIH
complex containing a kinase-inactive CAK was shown
to support in vitro transcription [53-55]. Moreover a
temperature sensitive allele of CDK7 was compatible
with adult survival in Drosophila, further indicating that
CAK activity may be dispensable for basal transcription
[56]. These observations led to the assumption of a
merely structural role of CAK during transcription.
However, it is important to point out that most if not
all the studies addressing the effects of XPD and CDK7
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mutations on transcription relied on in vitro transcrip-
tion assays limited to a restricted number of promoters.
Thus, it cannot be excluded that the enzymatic activities
of XPD and CAK are required for transcription activa-
tion in vivo. In particular, while basal transcription may
indeed not require CAK, this complex is still likely to be
involved in the regulation of transcription of a subset of
inducible genes.
TFIIH contributes to transcription at several early
stages of the transcription cycle. While the most obvious
contribution is opening of the transcription bubble via
helicase activity of XPB, TFIIH also directly interacts
with a variety of transcription activators and repressors
that deliver signals to, and receive signals from, the
transcription machinery. In addition, CDK7-dependent
phosphorylation of the carboxy-terminal domain (CTD)
of the largest subunit of RNA Pol II is required, along
with the action of the pause factors DSIF and NELF, for
proper promoter proximal pausing and 3’ pausing [30].
Polymerase pausing enables the recruitment of factors
involved in mRNA capping as well as of additional pro-
teins that contribute to the transcription and processing
of RNAs in a gene-specific manner. At promoters with
paused polymerase productive transcription elongation
can be rapidly triggered by CDK9/PTEFb, which phos-
phorylates DSIF and NELF as well as the CTD of RNA
Pol II. Importantly, some transcription factors activate
transcription at the level of elongation by mediating the
recruitment of CDK9 to the paused initiation complex.
In mouse embryonic stem cells the transcription factor
c-MYC was demonstrated to exploit this strategy to
activate gene transcription [57]. Direct modulation of
RNA Pol II pausing both at the 5’ and 3’ end of genes is
emerging as an important regulatory mechanism in par-
ticular for genes involved in development or genes that
need to be rapidly co-regulated in response to stimuli.
Intriguingly, this is in line with the observation that
CDK7 activity is essential during embryogenesis and
gametogenesis as well as for mounting transcriptional
responses to environmental stress such as heat shock
[30,57-61].
Transcriptional changes affecting particular genes or
groups of co-regulated genes, rather than reduced levels
of basal transcription, may underlie some of the NER-
independent phenotypes caused by XPD mutations. The
transcriptional profiles of cell lines isolated from TTD
and XPD patients revealed alterations of only a relatively
small subset of the transcriptome, including down- and
up-regulated genes [62,63]. In addition, the XP- and
TTD-type mutations analyzed in these studies affected
transcription of the downregulated genes to a similar
extent, indicating that the transcription defect is prob-
ably not a prerogative of TTD as previously believed.
Remarkably, a mutant cell line derived from a cancer-
prone XP-CS patient presented a high number of over-
expressed genes, mainly encoding proteins that are
involved in the regulation of cell proliferation, differen-
tiation and transformation [62]. Thus transcriptional
alterations may also contribute to the increased suscept-
ibility to carcinogenesis in XP and in the combined
syndromes.
Although part of the transcriptional changes accompa-
nying XPD mutations are certainly caused by the cellular
stress generated by defective NER, the finding that CAK
is involved in the regulation of RNA Pol II pausing
raises the possibility that some mutations in XPD may
affect preferentially the transcription of genes that
strongly rely on this mechanism for timely and coordi-
nated expression. Another intriguing, poorly explored
possibility is that mutant XPD alleles display differences
in their ability to undergo protein-protein interaction
with specific transcription factors.
Cell cycle regulation by the CAK complex
Cyclin dependent kinases regulate the cell cycle, inte-
grating activating signals and signals from various
checkpoints that ensure that each event of the cell cycle
occurs when the previous phase has been successfully
completed. The activity of CDKs is controlled in a
tightly timed manner by the availability and levels of
cyclins, by the association of specific regulators and by
various phosphorylation and autophosphorylation
events. Aside from its involvement in gene transcription
and NER, XPD is also a regulator of cell proliferation.
XPD affects cell cycle progression directly by regulating
CDK7, a critical activator of CDKs. Amongst the most
relevant targets of CDK7 for the cell cycle are the
cyclin-dependent kinases CDK1, CDK2, CDK4 and
CDK6. Phosphorylation by CDK7/CAK is necessary for
full activation of these kinases, which subsequently pro-
mote the phosphorylation of key cell cycle substrates.
Reducing CDK7 protein levels in Drosophila by the
use of the conditional cdk7ts1 allele disclosed mitosis as
the cellular process with the highest requirement for
CDK7 activity, being the first to be affected at the
restrictive temperature [56,64]. Interestingly, reduction
by half of the gene dose of XPD resulted in a partial res-
cue of the cdk7ts1 phenotype, indicating that mitotic
progression is facilitated by the lowered XPD levels [37].
Because XPD anchors CAK to TFIIH, the simplest
explanation is that reduced XPD levels release more
CAK in a form that has more access to and/or more
activity towards CDK7’s cell cycle targets. At least in
surviving animals such reduced XPD levels do not
appear to be detrimental for transcription activity, which
is again consistent with transcription requiring less
CDK7 kinase activity than mitosis and with the recessive
nature of the XPD mutant phenotypes that implies that
one functional copy of XPD is sufficient. Moreover, in
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embryonic insect cell lines RNAi knock down of XPD
resulted in increased rates of cell division without
obvious reduction in cell volume, indicating that XPD is
not limiting for bulk transcription as the residual levels
of XPD were sufficient to sustain growth of hyperproli-
ferating cells. Overexpression of XPD in fly embryos
also indicated a cell cycle inhibitory function of XPD as
it resulted in cell cycle arrest at different phases and
even caused skipping of mitosis. The observed pheno-
types indicate that elevated XPD levels lead to an inacti-
vation of mitotic CDK activity possibly because XPD
acts a molecular dispatcher for CDK7 by sequestering it
in the form of a TFIIH-CAK complex, or possibly a
XPD-CAK complex, and thereby hampering the phos-
phorylation of CDKs. Indeed, staining of embryos
expressing XPD from the strong heat shock promoter
revealed aberrant XPD and CDK7 accumulation at ecto-
pic sites in the cytoplasm [37]. Remarkably, regulatory
mechanisms seem to be in place to maintain constant
cellular levels of XPD, as overexpression of a XPD con-
struct did not result in the expected high levels of the
protein product (our unpublished data). Thus, ectopic
localization of XPD and perhaps CDK7/CAK may reflect
sites of proteolytic degradation. Consistent with regu-
lated XPD degradation, XPD was shown to interact with
several components of the proteasome in a yeast four
hybrid assay [52].
In Drosophila blastoderm embryos and cultured cells,
XPD is redistributed and possibly down-regulated in the
early part of mitosis [37]. Thus, under physiological con-
ditions the oscillating levels of cellular XPD may deter-
mine the localization and the fate of the CDK7-CAK
complex and thereby the phosphorylation of the differ-
ent CDK7 substrates (Figure 4). As the bridging subunit
of the TFIIH-CAK complex XPD is pivotal in orches-
trating the processes of mitosis and transcription, as
well as mitosis and repair, in a mutually exclusive man-
ner. During interphase (or in response to DNA damage)
higher levels of XPD ensure the integrity of the TFIIH
complex supporting transcription (or repair). At the
same time XPD prevents improper cell division by
sequestering CAK. In contrast, during mitosis the integ-
rity of the TFIIH complex is not critical whereas phos-
phorylation of CDK1, which is performed by the CAK
complex without core TFIIH, is essential [38]. Reduced
levels of XPD during mitosis may then allow the release
of sufficiently high amounts of free CAK for proper
phosphorylation of CDKs.
Mutations in XPD that modify the interaction of the
CAK (or the XPD-CAK) subcomplex with the core TFIIH
may result in dissociation of free CAK complex that may
then acquire higher affinity for cell cycle substrates such
as CDKs. In addition, reduced association of the CAK sub-
unit also disturbs the functionality of the TFIIH complex
itself. According to the model described in Figure 4, such
mutations are likely to lead on one hand to increased
mutagenic rates and misregulated transcription and on the
other hand to enhanced proliferation. The latter is
achieved at the expense of checkpoints and accuracy. This,
together with the elevated chances of unrepaired DNA
damage, increases the chance of cells becoming tumori-
genic. In contrast, mutations that affect the conformation
of XPD and thereby the stability of TFIIH, like the ones
found in the cancer-free TTD syndrome, are thought to
impact the function of TFIIH in transcription and repair.
Intuitively, reduced stability of the TFIIH complex would
be expected to result in increased levels of free CAK, and
thus increased cancer risk, analogously to reduced XPD
levels. However, various reports indicated that destabiliza-
tion of the TFIIH complex caused reduced levels of all
measured components, including the CAK subunits, thus
leaving no excessive free CAK that would promote over-
proliferation [65].
A quaternary complex containing all three CAK subu-
nits plus XPD was described in Drosophila embryos as
well as in mammalian cells [27]. Its biological relevance,
however, remained unknown. One possibility is that
XPD sequesters CAK into an inactive quaternary com-
plex, independent of the remaining TFIIH core. If this is
true, mutations that affect only the interaction of XPD
with TFIIH, but retain efficient binding to CAK, are
expected to be found in patients showing characteristics
of the cancer free XPD disorders. If in contrast this
XPD-CAK complex represents an active form of the
CAK complex, then such XPD mutations are expected
to result in sustained phosphorylation of mitotic sub-
strates and thus to be associated with increased cancer
incidence in the human disease.
XPD regulation of mitotic kinase
The phenotypes resulting from the modulation of XPD
protein levels clearly indicate that XPD controls the cell
cycle by functioning as a molecular dispatcher that
directs the subcellular localization of CAK and thereby
defines its substrate availability. However, it is not trivial
to isolate the cell cycle functions of XPD from its other
functions. An experimental setting where transcription
and NER are not needed, would allow to specifically
address the cell cycle role of XPD. Such a situation is
found in the young Drosophila embryo. Drosophila
embryos lacking XPD show several mutant phenotypes,
including general loss of division synchrony, problems
in spindle targeting, and numerous mitotic defects.
Mitotic defects appear to be mediated by a loss of CAK
control and ensuing deregulation of mitotic kinase activ-
ity as they can be partially rescued by reducing the
levels of the limiting CDK1 partner Cyclin B (CYCB)
[66]. In the absence of XPD, embryos show increased
tendency to improperly segregate chromatin. They
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display aberrant nuclear figures with chromatin bridges
and loss of chromosomal material, indicative of a strong
chromosome instability phenotype.
The activity of the mitotic kinase CDK1 is required to
enter mitosis and its downregulation at the anaphase
transition is a prerequisite for mitotic exit. Embryos
lacking XPD build up CDK1 activity normally as indivi-
dual nuclei enter mitosis. In contrast, its downregulation
and with it mitotic exit are delayed. While in normal
embryos CDK7 is progressively removed from the chro-
mosomes during mitotic exit, in the absence of XPD
excessive localization of CDK7 is seen on anaphase
chromosomes, this is reflected by the persistence of
phosphorylated histone 3 over the entire chromosomes
through ana- and sometimes even telophase, indicative
of mitotic kinase hyperactivity [66]. It is currently not
clear how prolonged chromosomal CDK7/CAK activity
would prevent CDK1 inactivation, as this process
depends mainly on CYCB degradation. One possible
explanation emerging from the results by Li and collea-
gues [66] is that lack of XPD and misregulated CAK
prevent this degradation possibly due to excessive
T-loop phosphorylation of CDK1, which allows and
stabilizes the interaction with CYCB [64,67]. A simple
explanation would be that M phase cyclins are more
easily degraded if they are only loosely associated with
CDK1. This model would then also suggest that CDK1
normally gets dephosphorylated in its T-loop to allow
efficient and rapid cyclin degradation, a pre-requisite for
normal exit from mitosis. This view is challenging the
initial assumption that T-loop phosphorylation is not
dynamic, however it is supported by evidence for a
more dynamic process both in Drosophila embryos and
in human cells [37,56,64,68]. Conversely, for mitotic
entry to occur CDK1 phosphorylation by CAK is
required to promote the formation of a stable CDK1-
CYCB complex [69]. Cyclin B binding and phosphoryla-
tion by CAK are essential CDK1 activation steps and
both steps occur in a concerted manner in the cell. The
phenotype of the embryos lacking XPD now suggests
that at the end of their round of duty the two processes
are linked again and that T-loop dephosphorylation may
even be required for CDK1 inactivation and possibly
Cyclin B destruction [66]. Indeed, there is evidence that
dephosphorylation of the CDK1 T-loop is part of the
normal mitotic exit in young Drosophila embryos during
Figure 4 Model for the role of XPD as a molecular dispatcher directing CAK localization according to the cellular requirements for
transcription, DNA repair and mitotic progression. During transcription and repair XPD is tightly associated with the TFIIH complex and
recruits the CAK complex, which is necessary for the phosphorylation of different substrates such as nuclear receptors (NR), transcription factors
(TF), the C-terminal domain of RNA Pol II (Pol II-CTD) as well as proteins involved in the DNA damage responses including p53. During the cell
cycle XPD levels seem to fluctuate in some cell types. At prometaphase reduced levels of XPD (or altered affinities) allow the release of CAK
from the core TFIIH complex (cTFIIH). Free CAK promotes mitotic entry by facilitating phosphorylation of the T-loop of the mitotic kinase CDK1,
which is necessary for the formation of functional Cyclin-CDK complexes. Mitotic exit can occur only upon downregulation of mitotic cyclins,
which may require prior dephosphorylation of the CDK1 T-loop. During exit from mitosis and interphase or during DNA-damage induced cell
cycle arrest, high levels of XPD may prevent persistent activation of the mitotic kinase by relocating CAK away from its mitotic substrates.
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the later nuclear division cycles because phosphorylation
is reduced during interphase [70]. Furthermore, a
requirement for dephosphorylation of the T-loop Thr of
CDK1 was also described for fission yeast mitotic exit,
where overexpression of a phosphomimetic CDK1T161E
causes cell division defects in anaphase [71]. The mode
of regulation summarized in Figure 4 is proposed based
on the analysis of a peculiar embryonic cell cycle, which
consists only of alternating S and M phases with no
requirement for transcription. It remains to be tested
whether this model holds true also in a complete diploid
cell cycle. Interestingly, reduction of XPD in human
cells also causes spindle and chromosome segregation
defects [28]. However a possible connection to the regu-
lation of mitotic kinases has not been investigated.
Role in checkpoint activation
DNA damage and replication checkpoints, induced dur-
ing interphase, maintain genome stability by delaying
cell cycle progression to allow time for DNA damage
repair to occur or for DNA replication to be completed.
DNA damage may also induce apoptosis, actively killing
cells when repair did not occur or the damage was too
severe. This safety mechanism eliminates potentially
deleterious mutants from a cell population. Which
checkpoint cascade is activated depends on the cell
cycle stage, on the type of damage and on the interven-
ing repair pathway [72-74].
The checkpoint cascade triggered by the type of DNA
damage repaired by NER culminates with the inhibition
of CDKs. Briefly, DNA lesions are recognized by a net-
work of sensor and mediator factors that result in the
rapid recruitment of the PI3K-related kinase ATM-Rad3
related (ATR) to the site of damage, this kinase then
activates CHK1, which ultimately leads to cell cycle
arrest by impinging at various level on the Cyclin-CDK
system (reviewed in [72-74]). The response to DNA
damage consists of a rapidly induced transient cell-cycle
delay (the CDC25 branch), which is eventually replaced
by a slowly operating sustained cell cycle arrest (the p53
branch). Phosphorylation by CHK1 leads to ubiquitina-
tion and proteasome-mediated degradation of the CDK-
activating phosphatase CDC25. Inactivation of CDC25
prevents the removal of inhibitory phosphorylation on
CDKs and causes a transient cell cycle delay. In addition
DNA damage repair kinases target p53 ultimately lead-
ing to the transcriptional activation of various genes
that are part of a p53 transcriptional program. The p53
response requires several hours as it depends on the
accumulation of p53 and of its targets, in particular the
CDK inhibitor p21. In contrast to the transient CDC25
response the p53 response can be protracted and, if the
lesions are too extensive, p53 can predispose the cells to
apoptosis by upregulating the expression of the proa-
poptotic proteins BAX and MDM2. Thus the p53
branch constitutes an important antitumoral barrier that
prevents the expansion of cells bearing unrepaired DNA
damage. If on the other hand the damage is removed
promptly and the repair events completed, p53 becomes
ubiquitinated and the cell-cycle arrest is relieved. Thus
the outcome of the repair process - be it successful
repair or the failure to remove the damage - has to be
communicated to the checkpoint pathway in order to
promote cell cycle resumption or cell death.
Initial processing of the DNA lesions by NER is neces-
sary to allow checkpoint complexes to bind stably to
UV-damaged chromosomes in order to monitor the
repair process and sustain the cellular responses. Defects
in components of the GG-NER pathway and in various
TFIIH subunits (i.e. TTDA, XPB and XPD) result in
totally or partially defective checkpoint activation upon
UV irradiation [29]. In contrast, the TC-NER subpath-
way is dispensable for checkpoint activation and indeed
patients carrying mutations in TC-NER-specific genes
present a strong epidermal cytotoxic response upon
UV-exposure which probably prevents precancerous
skin lesions from developing into cancerous lesions [75].
The primary function of the DNA-damage checkpoint
is to allow for efficient DNA repair, both by delaying
the cell cycle and by sustaining the activity of the DNA
repair mechanisms. In ATR-dependent phosphorylation
of XPA promotes enhanced XPA activity and thereby
increases the efficiency of NER and cell survival upon
UV irradiation [76]. Also the early events of the p53
response promote repair in part by promoting the
expression of GG-NER-specific factors, such as the XPE
binding partner DDB1 [77]. In addition, after the differ-
ent components of NER have assembled correctly at the
site of damage, inhibition of the helicase activity of XPB
and XPD by p53 is thought to block the translocation of
the TFIIH along the DNA, thus favoring the formation
of a stable complex and with this the precise removal of
the damage [78].
Failure to repair UV-induced DNA damage triggers
p53-mediated apoptosis, interestingly also this response
was shown to require functional XPD and XPB heli-
cases, further suggesting that mounting of the NER
response is a prerequisite for full activation of the p53
pathway [79]. Furthermore, TFIIH may also contribute
to the sustained p53 response to persistent DNA
damage via its kinase activity, as p53 is a substrate for
phosphorylation by the CAK complex [80].
Regulation of MYC expression and activity
TFIIH exerts growth control also by regulating the
expression levels of the transcription factor MYC, as
this was reported to be deregulated in XPD- and XPB-
deficient human cell lines [81,82]. Notably, MYC has a
conserved role in coordinating many essential processes,
including proliferation, growth, differentiation,
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metabolism and apoptosis. As a consequence of its
pivotal role as a growth regulator, even slight distur-
bances of MYC expression directly influence the size
and growth rate of cells in culture and in vivo, where
oncogenic activation of MYC occurs in a variety of
tumors [83]. This raises the intriguing hypothesis that
deregulation of MYC expression may be connected to
the increased cancer proneness of XP patients. MYC
exerts its function by controlling the expression of
nearly 10% of the whole genome; it binds to a E-box
motif in the 5’ region of target genes and promotes
transcription elongation by recruiting P-TEFb/CDK9,
which in turn releases the poised RNA Pol II complex
[57]. Binding to the consensus sequence requires het-
erodimerization of MYC with either MAX or MAD pro-
teins, and the interaction partner determines whether
MYC will act as a transcriptional activator or repressor.
In addition, MYC was shown to generally influence
chromatin structure by promoting both ATP-dependent
remodeling of nucleosomes and histone acetylation, the
two major chromatin modifications involved in the reg-
ulation of transcription [83].
As a powerful positive regulator of growth, MYC
imposed the evolution of molecular constraints to
ensure that its synthesis and activation only occur at the
proper moment. At steady state the levels of the MYC
transcript as well as of the encoded protein are short-
lived and scarce. The promoter of MYC is subject to
tight and rapid regulation at the level of transcriptional
elongation by the antagonistic action of the transcrip-
tional activator FUSE-binding protein (FBP) and the
FBP-interacting repressor (FIR). Interestingly, the func-
tion of FIR and FBP requires the helicase activity of
TFIIH [84]. XPB and XPD mutations appear to simulta-
neously affect activation and repression of MYC tran-
scription, interfering with the fine-tuning of cellular
MYC levels. The effect of these mutations are highly
variable and while some cells or tissues may experience
reduced MYC activity and thus reduced proliferation,
elsewhere the overexpression of this oncogene may trig-
ger cancer [81].
Also the posttranslational regulation of MYC may
involve TFIIH. MYC stability and function are con-
trolled by a chain of interdependent phosphorylation
events, initiated by phosphorylation on a serine residue
by a proline-directed protein kinase such as MAPK or
CDK1. This phosphorylation stabilizes MYC and pro-
motes its activity, but in addition it provides the docking
site for the GSK3 kinase. Phosphorylation of MYC by
GSK3 initiates a series of regulatory events eventually
leading to the degradation of MYC [85]. The interaction
of TFIIH with CAK, controlled by XPD, determines the
substrate specificity of CDK7 and thus the activation
state of CDK1, which in turn regulates the early events
of the described MYC cycle. Thus XPD is involved in
the regulation of MYC levels both at the transcriptional
and the posttranscriptional levels. Deregulated MYC
activity by itself may not lead to cancer as MYC, besides
proliferation, also increases p53-mediated apoptosis by
suppressing anti-apoptotic proteins when the level of
growth factors are low. Hence a second hit mutation
impairing the apoptotic pathway, or a single mutation
affecting both pathways, is necessary for MYC-driven
tumorigenesis to occur [86]. Furthermore XPD and XPB
activities are required for both MYC regulation and
p53-mediated apoptosis [79,82]. These mutations are
therefore candidate for such a tumorigenic mutation as
they simultaneously increase cell proliferation and
reduce apoptosis.
In addition to transcriptional regulation, MYC can
also impact on mRNA translation by promoting cap
methylation. MYC-dependent cap methylation occurs
independently of transcription and does not require
binding to E-box elements in the promoter region [87].
Interestingly translation of CDK7- and CDK9-encoding
mRNAs is boosted by MYC-induced cap methylation
[88]. It appears therefore that the activities of MYC and
XPD converge on CDK7, antagonistically regulating its
activity, expression and spatial localization. Experiments
in mice fibroblasts demonstrated that MYC can also
affect cell cycle progression by positively regulating
CYCD and its cognate CDKs, CDK4 and CDK6, and by
inhibiting expression of their inhibitors p27 [89] and
p15INK4b [90]. Notably, CDK4 is also a target of CAK,
thus CDK7 and MYC cooperatively impinge on cell
cycle progression by regulating common targets as well
as each other.
A complicated genotype-phenotype relationship
A direct cause-effect relationship between inefficient
DNA repair and predisposition to tumors is not suffi-
cient to explain the elevated occurrence of cancer mani-
fested in XP-D patients since the cancer free COFS and
TTD syndromes are accompanied by similar defects in
repair. Neither can NER deficiency alone explain all the
clinical phenotypes in TTD such as the characteristic
brittle hair and the various neurological symptoms,
which are likely to involve also damage-independent
developmental processes, sensitive to transcription
alterations or to improper cell cycle regulation. Several
hypotheses have been formulated to explain the compli-
cated genotype-phenotype relationship of mutations in
the XPD gene. Notably, the hypotheses discussed here
are not mutually exclusive and it is likely that different
events concur in the definition of the complex XPD
phenotypes.
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The transcription defect hypothesis
The transcription defect hypothesis postulates that the
TTD and CS phenotypes are caused by subtle altera-
tions of transcription, due to reduced cellular levels of
stable TFIIH complexes [91]. This model also implies
that the absence of cancer in TTD, COFS and CS
patients is due to the reduced levels of basal transcrip-
tion that probably does not support the accrued protein
synthesis requirement of the fast growing tumor cells
or, alternatively, to the reduced transcription of one or
several factors required for tumor progression. Reduced
basal transcriptional levels were observed using in vitro
transcription assays and in vivo transcription of a repor-
ter gene. Results from these studies showed that XPD
mutations found in TTD patients, but not those found
in XP patients, strongly impaired the ability of a purified
TFIIH complex to sustain transcription of the reporter
[41]. However, this view is challenged by DNA microar-
ray studies showing that TTD and XP mutations affect
basal transcription to similar levels in human fibroblast
cell lines [62,63]. Interestingly, although they were lim-
ited to few disease-related point mutations, these studies
revealed distinct transcriptional signatures of UV-
irradiated human TTD, XP and XP-CS cell lines with
both up- and down-regulated genes. The cancer predis-
position in XP may also be explained with upregulation
of cell-cycle genes.
The type-of-damage hypothesis
Due to differences in metabolism and because not all
tissues are equally exposed to exogenous damaging
agents (for example the skin is more exposed to UV
than internal tissues), different cell-types display differ-
ent lesion spectra and thus put different demands on
DNA repair and damage responses. In addition, different
repair mechanisms are induced in different phases of the
cell cycle [72], implying that postmitotic and mitotic tis-
sue are different in terms of the kind of damage they
accumulate and of the cellular response elicited by this
damage. Depending on the specific NER subpathway
they affect (TC-NER or GG-NER), different mutations
in NER genes may more strongly affect specific tissues
and thus cause specific diseases. Defective DNA repair
also leads to progressive degeneration of cells not
exposed to UV. This has been attributed to inadequate
repair of oxidative damage that results from normal
metabolism. It is currently not known if and how much
of this physiological damage is repaired by NER and
would thus be affected by mutations in XPD. For exam-
ple neuronal death can be triggered by relatively low
levels of damage (probably of oxidative nature) in tran-
scribed genes that result in RNA Pol II stalling. As this
kind of damage is subject to TC-NER it is less efficiently
removed in patients with mutations in genes encoding
TC-NER components. Consistent with this model, XPC
and XPE patients, who retain proficient TC-NER, gener-
ally do not display neurological symptoms [11]. On the
other hand, there is good evidence in support of a defi-
ciency in repair of oxidative damage being the cause of
the progressive deterioration in CS, which may be parti-
cularly significant for tissues with high oxygen demand
such as the brain [92]. Can this explanation be applied
to explain the different syndromes associated with dis-
tinct mutations in XPD? As depicted in Figure 2, XPD is
involved in a common step of TC-NER and GG-NER,
after damage recognition. Thus, it may be expected to
affect both pathways in equal measure. However, muta-
tions in XPD do not always lead to neurological symp-
toms. One possible explanation compatible with this
model would be that mutations in XPD lead to neurolo-
gical defects if they affect the ability of the TFIIH
complex to be recruited by TC-NER-specific damage-
recognition complexes.
In addition to preventing damage repair, mutations in
genes encoding components of the NER pathway may
affect DNA damage signaling. Failure to activate the
checkpoint cascades contributes to genomic instability,
resulting in increased propensity to cancer. In contrast,
mutations that affect only the repair function of NER
genes are less likely to cause cancer, as the cell death
responses are still in place. Instead they may lead to
increased tissue deterioration as a secondary effect of a
proficient damage-induced senescence mechanisms [93].
Persistent signaling of the DNA damage checkpoint
leads to cell death. This can be circumvented by the
activation of the mechanisms of translesion DNA synth-
esis by either error-free or error-prone DNA poly-
merases. Replication through photoproducts requires
the sequential action of Polh (encoded by XPV) and
Polζ which are recruited by PCNA when this is monou-
biquitinated in response to stalling of the replication
fork [94]. Boyle et al. directly assayed the repair of UV-
induced damage in cells isolated from different patients
and found that TTD cells in comparison to XP cells
remove DNA damage at a normal rate, despite having
low TFIIH levels and impaired XPD helicase activity.
Interestingly, they observed a delayed recruitment of
repair proteins to the site of damage in both XP and
TTD cells; but while in TTD cells the reduced TFIIH
complex stability facilitates the dissociation of the repair
proteins from the damaged DNA, repair proteins per-
sisted at the site of damage in XP cells, presumably
hampering the access of the error-free DNA polymerase
h, encoded by XPV, and thus increasing genomic
instability [95].
In cells from XP-CS patients the NER machinery read-
ily detects UV-induced DNA damage and can initiate
repair. However, aberrant incisions are observed at
undamaged sites. It has been proposed that TFIIH exists
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in either a transcription competent or a repair compe-
tent conformation. Upon receiving a signal from the
damaged DNA, TFIIH may become activated into its
repair mode and recruited to the site of damage. If the
functional switch does not occur, there is no repair. If
the switch occurs in the absence of damage, this leads
to aberrant NER activation. Indeed, in XP-CS cells the
mode switch occurs promptly, but TFIIH is not relo-
cated from the sites of transcription, resulting in inci-
sion in the actively transcribed DNA rather than at the
lesion site. On one hand this increases the mutation
rate upon UV-exposure (causing the XP phenotype) and
on the other hand it may reduce gene expression due to
the introduction of DNA breaks at the sites of transcrip-
tional initiation (causing the CS phenotypes) [96].
The cell-cycle hypothesis
The function of XPD as a regulator of proliferation may
be responsible, at least partially, for the increased inci-
dence of neoplastic diseases in XP patients [37,38]. The
proposed model (Figure 4) postulates that high levels of
XPD negatively regulate cell-cycle progression by retain-
ing the CAK complex in the transcription and repair
competent TFIIH complex. Under normal conditions, at
mitosis or after DNA repair, cell-cycle progression
would be favored by reduction of XPD levels or its affi-
nity to CAK, resulting in increased levels of a free form
of the CAK complex and thus in higher affinity for
CDK substrates.
According to this model, whether or not XPD muta-
tions result in increased proliferation and cancer
depends on the affinity of the mutated protein for the
other subunits of the TFIIH complex as well as on the
stability of the XPD protein product. Mutations resulting
in a less stable protein or in a protein with reduced abil-
ity to sequester the CAK complex, preventing it from
performing its cell cycle function, are expected to lead
to increased CAK activity towards its CDK substrates
and thus to increase the proliferation of potentially
malignant cells. In contrast, mutations that result in per-
sistent interaction of CAK with TFIIH or mutations that
cause a destabilization of the whole TFIIH-CAK com-
plex would be antiproliferative as they would result in
reduced levels of activating CDK phosphorylation. The
antiproliferative effect of these mutations could explain
some of the developmental defects of the XPD disorders.
The genome instability hypothesis
Changes in chromosome number and structure are
commonly observed in tumors, many cancers exhibit
aberrant cell architecture, including abnormal centro-
somes, multipolar spindles, and breakage-fusion cycles.
Chromosomal instability can occur early during tumori-
genesis and promotes both tumor progression and het-
erogeneity [97].
By reducing the ability of cells to repair DNA damage,
defects in XP genes result in increased mutation rates,
in particular following exposure to UV irradiation. How-
ever, similarly increased mutations rates were observed
in related syndromes without neoplastic disease. This
indicates that the repair defect is necessary, but probably
not sufficient to trigger carcinogenesis. It is thus likely
that XP mutations also interfere with mechanisms other
than DNA repair, thereby causing additional chromo-
some instability.
Work in Drosophila unraveled a role for XPD in
maintaining chromosome stability during mitosis in part
by regulating the dynamic localization of CAK and thus
influencing the kinetics of CDK activity [66]. During the
syncytial divisions in Drosophila embryos XPD also
plays an additional function in the control of the mitotic
spindle dynamics, preventing misappropriation of chro-
mosomes by neighboring spindles. This novel role of
XPD should also lead to new insights into the molecular
basis of the neurodevelopmental defects and the neo-
plastic disease in XPD disorders.
The function of XPD in ensuring genome stability is
conserved in human cells as well, where the TFIIH-
independent XPD-containing complex MMXP has
recently been implicated in spindle organization and
chromosome segregation. Moreover, increased mitotic
defects were reported for human cell lines bearing XPD
mutations leading to the XP and XP-CS phenotype, but
not for an XPD mutation leading to TTD. While this
correlation still needs more extensive testing, these
results combined with the Drosophila results [66]
strongly suggest that chromosome instability is a major
factor underlying some of the XP symptoms, in particu-
lar the marked cancer predisposition.
The aging hypothesis
Malfunctioning of the mechanisms devoted to genetic
surveillance is a main cause of human progeroid syn-
dromes, characterized by the precocious appearance of
clinical and molecular features of natural aging [98].
Genetically these rare diseases are caused by mutations
in genes that are directly involved in DNA repair or in
genes encoding lamins A and C or molecules involved
in the post-translational processing of lamins [5]. The
latter indirectly affect DNA repair by impairing the
recruitment of checkpoint and repair factors to the site
of damage [99]. Moreover, the progressive loss of integ-
rity of the somatic genome is thought to causally contri-
bute to degenerative aging in normal individuals [93].
As mutagenic lesions may potentially promote cancer,
certain types of DNA damage trigger senescence as part
of a protective response. Thus aging may be the conse-
quence of compromised tissue functionality due to
the accumulation of senescent cells and to the loss of
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irreplaceable postmitotic cells or, in the case of renew-
able tissues such as the skin, to the depletion of prolifer-
ating stem cell pools [93,100]. Interestingly, mutations in
TC-NER specific factors as well as some XPD mutations
result in increased apoptosis in various tissues. Such
increased apoptosis may minimize cancer susceptibility
but is also likely to be the main cause of the characteris-
tic progeroid features of these patients.
The hormone signaling hypothesis
Additional targets of TFIIH-CAK phosphorylation are
members of the nuclear receptor family of transcrip-
tional activators including RARa, RARg and ERa
[31,101]. Mutations in XPD that affect the interaction of
CAK with TFIIH would result in the failure to properly
phosphorylate these nuclear receptors, contributing to
the phenotypes of the XPD syndromes, in particular
sterility, growth retardation, developmental defects, ske-
letal and ocular abnormalities.
The retinoic acid receptors (RARs) play critical roles in
the development and homeostasis of a variety of tissues.
During embryonic development retinoic acid signaling via
the RAR receptors is required for patterning and organo-
genesis, and mutations in RARs or vitamin A deficiency
can lead to growth retardation, sterility, ocular defects and
skeletal defects [102]. RA signaling is essential for granulo-
cyte differentiation and this may explain some of the
immune cell abnormalities in XP. As retinoic acid deriva-
tives have anti-proliferative and pro-differentiation proper-
ties, they are employed as preventive treatment and
successfully reduce skin carcinogenesis in XP patients
[103]. The mechanisms of action of retinoids is unclear,
but it may involve non-transcriptional effects that may or
may not depend on RARs [104].
Another nuclear receptor phosphorylated by TFIIH-
CAK is the estrogen receptor alpha (ERa) [101]. Defects
in transcriptional activation via ERa may be causative of
some of the observed developmental defects as well as
premature aging symptoms. Notably, during normal
aging the responsiveness to estrogen decreases. More-
over, estrogen is known to stimulate immune cells and
failures of the immune system may be associated with a
decreased anti-tumoral response. Also, the sterility of
some XPD patients could be directly linked to defective
estrogen signaling in particular during sperm maturation.
Several postnatal neurodevelopmental processes are
regulated by the thyroid hormone through nuclear thyr-
oid hormone receptors. Interestingly, the neurological
dysfunctions observed in TTD individuals have strong
similarities to thyroid hormone deficiency and deregu-
lated expression of thyroid hormone target genes was
observed in the CNS of a murine TTD model [105].
The immune system failure hypothesis
Natural killer (NK) cell activity is thought to be impor-
tant in the immune surveillance against neoplasia.
Moreover, since UV-induced tumor cells are generally
highly antigenic, they may be lysed by cytotoxic T cells
following antigen presentation to helper T cells by
Langerhans cells (LC). Unfortunately, besides inducing
carcinogenic DNA lesions, UV can also counteract this
antitumoral response by exerting immunosuppressive
action [106].
Lehman et al. (1989) proposed that the cancer-prone
XP phenotype may be caused by reduced antitumoral
immune response, possibly as a result of a second reces-
sive mutation [107]. This hypothesis was based on the
observation that some XP patients show reduced levels
of NK cells in the peripheral blood, in addition to NER
defects [108]. Successively, other groups evaluated the
phenotype of circulating lymphocytes and the activity of
NK cells in XP and TTD patients and in their relatives
with variable results. Heterogeneous levels of NK cells
were found in most patients and some of their heterozy-
gous relatives and they do not appear to correlate with
increased skin cancer lesions [109,110]. Additional
defects in the maturation of NK cells may play a role in
XP patients, such as reduced secretion of lymphokines
by immunoregulatory T cells.
If deregulated NK cell activity is indeed due to an addi-
tional recessive mutation in a distinct locus, one would
expect to find among the relatives of XP patients indivi-
duals with compromised immune response but without
the typical XP phenotypes, as well as individuals with NER
defects and normal NK cell activity and thus normal
antitumoral immune response. This is indeed the case;
malignant cutaneous neoplasms develop in (only) approxi-
mately 45% of XP patients [8] and immune defects have
been reported also in healthy relatives of patients with XP
[109,110]. However, it cannot be excluded that impaired
NER function in XP patients indirectly affects a pathway
required for the differentiation or the activity of immune
cells, in particular of NK cells. Notably the DNA damage
response triggers the surface expression of NKG2D recep-
tor ligands in precancerous and cancerous lesions. This
receptor is expressed in various lymphocytes, including
NK cells, and is one of the major receptors required for
NK cell mediate lysis of tumor cells in vitro [111].
Impaired expression of NKG2D ligands or impaired
signaling upon DNA damage may underlie decreased anti-
tumor immunity in XP.
Current models for the study of XPD disorders and
function
Various human XPD/ERCC2 mutations have been intro-
duced into the corresponding murine gene and the disease
phenotypes recapitulate well the human syndromes,
although the relative severity of the cancer and neurologi-
cal defects in specific mouse mutants has been somewhat
unpredictable [112,113].
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The establishment of a reliable technique to isolate
skin fibroblasts from human patients affected by XPD
syndromes and of several well-established cell-based
assays allowed to directly address various molecular
aspects of the disease and to compare the relative activ-
ity of the mutated alleles and the stability of the mutant
proteins. Moreover, it has rendered possible to identify
the causative mutation by genetic complementation.
Most of these lines are available through the Coriell
Institute for Medical Research (Camden, NJ, USA). This
will allow in the future to more reliably compare results
from different laboratories. Primary fibroblasts from
human patients were used mainly to assess the sensitiv-
ity to the killing effects of UV irradiation, to study the
repair DNA synthesis (or unscheduled DNA synthesis)
and the recovery of RNA synthesis after UV irradiation.
Recently, cDNA microarray studies were also performed
on some of these lines in order to define a possible
distinctive transcriptional defect signature that may
partially explain the heterogeneity of these syndromes.
A fundamental obstacle to the study of the cellular
pathways involving XPD is posed by the concurrence of
various processes requiring the presence and/or the
function of XPD. In this respect, the Drosophila early
embryo was used successfully to isolate the cell cycle
function of XPD from its requirement during transcrip-
tion and NER. Using XPD-deprived young Drosophila
embryos it was possible to discover a novel important
role for XPD in maintaining genome stability during
mitotic divisions. Introducing mutations found in the
human diseases into the Drosophila XPD gene should
therefore reveal which of these mutations affect this par-
ticular function and to which extent this may contribute
to the disease.
Implication for the treatment of NER syndromes
One of the most devastating aspect in many NER- and
XPD-syndromes is the neurological component and
understanding, which molecular defects are responsible
for neurodegeneration is important for the development
of therapeutic strategies. The neuropathology can be
very different between syndromes and its causes include
neurodevelopmental defects and progressive neurode-
generation (i.e. loss of neuronal cells as seen in XP) and
defective myelination (with either reduced levels of mye-
lin or abnormal myelin as observed in CS, COFS and
TTD) [114]. For reviews covering the relationship
between DNA repair and neurological diseases the
reader is referred to specialized reviews [11,50,115].
During the rapid cellular proliferation of neural progeni-
tors genomic stability is of paramount importance as
these cells will populate the nervous system where they
remain in place throughout the remaining life. Expan-
sion of progenitor cells that incurred mutations or cell
loss due to apoptosis (in response to unrepaired DNA
damage) could subsequently lead to disease. The possi-
ble role of XPD in preserving genomic stability during
the early embryonic cell cycles, as seen in Drosophila,
therefore provides an additional theoretical mechanism
for the developmental neuropathology in XPD syn-
dromes. In differentiated cells, DNA repair and in parti-
cular NER, remain extremely important to maintain the
integrity of the nervous system. Damage from endogen-
ous sources is likely to be relevant in causing oxidative
and other types of damage that are repaired by NER.
Terminally differentiated neuronal cells show reduced
GG-NER activity per se. Moreover, these cells are
exposed to more oxidative damage than other cells
because of their high oxygen requirements and in addi-
tion they transcribe a large portion of their genome,
which makes them more susceptible to subtle defects in
transcription on one hand, and to damage dealt with by
TC-NER on the other hand. In TTD, CS and COFS the
most striking neuropathological feature is abnormal
myelination, indicating that oligodendrocytes rather
than neurons are affected. In TTD, aberrant myelination
is due to the loss of the co-activator function of TFIIH
in thyroid hormone-dependent gene expression [105]. In
addition, apoptotic cells may induce an inflammatory
response resulting in increased oxidative stress and, in
turn, in more unrepairable DNA damage. In contrast to
neurodevelopmental defects, that are more difficult to
approach therapeutically, postnatal neuropathology may
in the future be treated. To the extent that oxidative
lesions are involved in neurological disease in XPD-
syndromes, which still awaits conclusive prove, antioxi-
dants or other drugs that prevent their formation may
be useful. Additional degenerative phenotypes reminis-
cent of physiological aging are likely due to cell death
and loss of regenerative potential of various differen-
tiated tissues due to loss of stem cells (subcutaneous fat
tissue, hematopoietic stem cells, endocrine cells, various
cells of the eye and multiple organs) [7].
One of the main causes of morbidity in XP patients is
the development of tumors, in particular skin tumors,
because 2 out of 3 XP patients die before reaching
adulthood due to metastases. Early diagnosis is impor-
tant because preventive measures have to be applied
immediately after birth. The studies of Fan et al. (2008)
and Dubaele et al. (2003) now indicate that impaired
XPD helicase activity correlates with phenotypical mani-
festations characteristic of XP. Assessment of XPD
helicase activity or theoretical prediction based on struc-
tural data could be standardized as diagnostic strategy.
Attempts to attain canceroprotective effects with sys-
temic administration of retinoids (chemoprevention)
have been made [103,116]. This therapeutic strategy was
rather successful in preventing the development of new
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skin cancers but unfortunately the benefits ceased when
the treatment was discontinued and the long term
administration of retinoids is limited by their side-
effects. The precise mechanism by which retinoids act
as chemopreventive agents in unknown, but many of
the wide variety of effects elicited by retinoids are
mediated through binding of nuclear receptors. This
implies that the beneficial effects of this chemopreven-
tion may be restricted to patients with XPD mutations
that do not interfere with CAK-dependent activation of
these nuclear receptors. A better understanding of the
implication of nuclear receptor activation in the pato-
physiology of XPD disorders is therefore required to
select patients for systemic treatment with retinoids.
While the primary causative agent of skin neoplasia is
certainly UV irradiation, the causes of increased internal
cancers are unknown. Internal cancers are most fre-
quently reported in the gastrointestinal trait and lungs,
which are more exposed to environmental carcinogens.
Thus, these patients may benefit from antioxidants as
chemopreventive agents. Finally, while the NER defect is
certainly playing a fundamental role in the mechanism
of neoplasia in XP patients, the contribution of other
XPD-dependent processes still needs to be studied, par-
ticularly relevant in this context is the involvement of
XPD in cell cycle regulation and maintenance of gen-
ome stability.
Conclusions
The rare human hereditary disorders termed NER syn-
dromes are caused by mutations in genes encoding
components of the NER pathway. The most striking
symptoms of these syndromes involve two different tis-
sues, namely the nervous system and the skin. Due to
defects in the GG-NER, XP patients cannot cope with
DNA lesions caused by UV-irradiation and accumulate
various abnormalities in exposed tissues such as the
eyes and the skin, including precancerous lesions. Such
lesions frequently progress to become cancerous lesions
because also the apoptotic response to DNA damage is
impaired in these patients. In patients of the comple-
mentation group D, we propose that additional mechan-
isms may be implicated in the cancer pathogenesis. XPD
impinges on the mechanisms of cell cycle regulation by
ensuring that CAK is restrained from phosphorylating
its mitotic substrates during the process of DNA repair.
Failure to properly arrest the cell cycle in XPD mutant
cells may result in the expansion of cells that have not
terminated the repair of potentially mutagenic muta-
tions, thus contributing to the process of tumorigenesis.
In some XPD disorders, neurological symptoms add to
the neoplastic disease. Some of these neurological symp-
toms are the consequence of neuronal death resulting
from defective repair of oxidative lesions that are
frequent in the nervous tissue due to its high oxygen
consumption, moreover defective transcription or defec-
tive repair of transcribed genes may cause neuronal tis-
sue abnormalities. Finally XP-D patients may be
predisposed to neurodegeneration due to the loss of an
additional function of XPD in maintaining somatic gen-
ome stability. Step by step the molecular and cellular
functions of XPD start matching the complexity of the
disorders associated with XPD and one wonders what
other functions still wait to be uncovered.
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